SMMT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SMMT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Summit Therapeutics's Revenue per Share for the three months ended in Dec. 2023 was $0.00.
During the past 12 months, Summit Therapeutics's average Revenue per Share Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Summit Therapeutics was 306.40% per year. The lowest was -89.40% per year. And the median was -45.00% per year.
For the Biotechnology subindustry, Summit Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Summit Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Summit Therapeutics's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Summit Therapeutics (NAS:SMMT) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of Summit Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Ankur Dhingra | officer: Chief Financial Officer | C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Maky Zanganeh | director | 51 ADAM WAY, ATHERTON CA 94027 |
Manmeet Singh Soni | director | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085 |
Robert W Duggan | director, 10 percent owner, officer: See Remarks | 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756 |
Yu Xia | director | 6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437 |
Robert F. Booth | director | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Alessandra Cesano | director | 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065 |
Urte Gayko | director | C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Kenneth A Clark | director | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085 |
Jeffrey R Maranian | officer: VP, Corporate Controller | C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Luhua Wang | director | ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
David Jonathan Powell | officer: Chief Scientific Officer | ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Camilla Graham | officer: Chief Clinical Affairs Officer | ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Ventzislav Stefanov | director, officer: See Remarks | ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Ujwala Mahatme | director | ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
From GuruFocus
By Business Wire 03-21-2023
By Business Wire 03-03-2023
By Stock market mentor 01-23-2023
By Business Wire 05-09-2023
By sperokesalga 02-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.